ClinicalTrials.gg
CompletedNCT03815318Updated Feb 6, 2020

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

A Phase 3 interventional study of Recombinant Human Coagulation FVIII in Hemophilia A, sponsored by Sinocelltech Ltd.. Completed at 1 site in China. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-02-06.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
27th of 80
73 · median 54
Started
2019
with 5 others
Phase 3
41 of 93
9 open now
Registered
29th of 93
by date
Lead sponsor
5 of 93
Sinocelltech Ltd.

Among the 93 studies in Hemophilia A with a site in China, this one is the 27th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2019, is one of 41 in phase 3, and was the 29th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open-label, single-arm trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (≥12 years old) with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII:C) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from V1 and prophylaxis with SCT800 shall continue for 24 consecutive weeks.

Read the detailed description

After subjects pass screening, prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week for 6 months. Subjects shall receive FVIII intravenous injection treatment at the study site or at home. During the study prophylaxis treatment period, subjects should return for visit every four weeks, namely for Visit (V) 2 (4 weeks ± 4 days), Visit 3 (8 weeks ± 4 days), Visit 4 (12 weeks ± 4 days), Visit 5 (16 weeks ± 7 days), Visit 6 (20 weeks ± 7 days), Visit 7 (24 weeks ± 7 days) and end-of-treatment (EOT) visit (+ 14 days). Of which, blood collection shall be carried out during the screening period and in V1, V2, V4, V7 and the EOT visit for FVIII inhibitor assay; blood collection shall be carried out before and after the completion of SCT800 infusion in V1, V4 and V7 for incremental in-vivo recovery (IVR) assay.

FVIII:C activity shall be monitored before injection and 15minutes(min), 30min, 1h, 3h, 6h, 9h, 12h, 24hours(h), 28h, 32h and 48h after injection at V1 and V7. Then pharmacokinetics parameters (incremental in-vivo recovery, t1/2 etc.) of SCT800 shall be calculated and evaluated.

5 subjects may receive elective surgical treatment within the prophylaxis treatment period (after the first drug administration in day 0).

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥12 years old and ≤65 years old;
  • Male patients who are clinically diagnosed with severe (laboratory tested FVIII:C \<1%) hemophilia A, including historical FVIII:C \<1%;
  • Previously received FVIII treatment (prophylactic or bleeding treatment), have the relevant records and are verified to have accumulated exposures days( EDs) ≥150 days;
  • The bleeding treatment records of at least 3 months before screening can be obtained;
  • Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result \<0.6 BU(Bethesda unit)/mL);
  • The is normal or international normalized ratio (INR) ≤1.5; 7. count ≥100 × 109/L;

Exclusion criteria

Exclusion Criteria:

  • Known allergy to recombinant coagulation factor VIII concentrate or any ; known allergy to bovine, rodent or hamster bovine;
  • Has a history or family history of blood coagulation factor VIII inhibitor;
  • Clinical liver function test (glutamic-pyruvic transaminase, glutamic-pyruvic transaminase) ≥ three times the (ULN) or clinical kidney function test (blood urea nitrogen, creatinine) ≥ three times the ULN;
  • Patients clinically diagnosed with active or ;
  • Patients with other coagulation dysfunction diseases in addition to hemophilia A;
  • Patients with severe heart disease, including myocardial infarction and cardiac dysfunction of class III or above;
  • Patients who previously experienced intracranial bleeding;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Recombinant Human Coagulation FVIII

    Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.

    Drug: Recombinant Human Coagulation FVIII

Interventions

  • Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.

    Also known as: SCT800

06

What researchers measure

Primary outcomes

  1. Annualized Bleeding Rate

    Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)

    Time frame: up to 24 weeks

Secondary outcomes

  1. Annualized joint bleeding rate

    Annualized joint bleeding rate(AJBR) can be calculated using the following formula: Number of joint bleeding events during efficacy evaluation period/(number of days in treatment period/365.25).

    Time frame: up to 24 weeks

  2. FVIII incremental in-vivo recovery

    Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as \[IU/ml\]/\[IU/kg\]

    Time frame: Predose within 30 min,15 min±2 min、1 hour±5 min.

  3. Bleeding event treatment efficacy

    The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).

    Time frame: up to 24 weeks

  4. Elimination Half Life

    t1/2; One-stage aPTT Clotting Assay and Chromogenic Assay

    Time frame: Predose within 30 min,15 min±2 min、30 min±2 min,1 hour±5 min,3 hours±5 min,6 hours±5 min,9 hours±10 min,12hours h±10 min,24 hours±10 min,28 hours±10 min,32 hours±10 min and 48 hours±10 min post-dose.

  5. Clearance

    CL; One-stage aPTT Clotting Assay and Chromogenic Assay

    Time frame: Predose within 30 min,15 min±2 min、30 min±2 min,1 hour±5 min,3 hours±5 min,6 hours±5 min,9 hours±10 min,12hours h±10 min,24 hours±10 min,28 hours±10 min,32 hours±10 min and 48 hours±10 min post-dose.

  6. Area Under the Curve to the Last Measurable Timepoint

    AUClast;One-stage aPTT Clotting Assay and Chromogenic Assay

    Time frame: Predose within 30 min,15 min±2 min、30 min±2 min,1 hour±5 min,3 hours±5 min,6 hours±5 min,9 hours±10 min,12hours h±10 min,24 hours±10 min,28 hours±10 min,32 hours±10 min and 48 hours±10 min post-dose.

Other outcomes

  1. Incidence of FVIII inhibitors

    The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial.

    Time frame: up tp 24 weeks

07

Study locations

1 site
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jan 2020, 11 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 24, 2019
StartActual
Jan 21, 2019
Primary completionActual
Jan 16, 2020
CompletionActual
Jan 16, 2020
Last update
Feb 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03815318
Lead sponsor
Sinocelltech Ltd.
Collaborators
Chinese Academy of Medical Sciences, Parexel, Q2 Solutions
Responsible party
Sponsor
First posted
Jan 24, 2019
Start date
Jan 21, 2019
Primary completion
Jan 16, 2020
Completion
Jan 16, 2020
Last update
Feb 6, 2020

Study contacts

Renchi Yang
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omfiloctocog alfa

Start the discussion